Cracking Complexity: Learnings From 70+ Bispecific Antibody Programs

Biologics pipelines are getting more complex by the day — and next-generation formats like bispecific antibodies are moving faster than ever toward the clinic. For early-stage biotech teams, that speed can create real uncertainty: Where do the biggest development risks actually live? How do early decisions ripple forward into IND readiness? And how do you move quickly without setting yourself up for costly rework down the road?

Lonza's technical experts have worked across more than 70 bispecific antibody programs, and they've seen the same patterns emerge again and again. In this webinar, they share what they've learned — across analytical development, downstream purification, and drug product formulation — about the challenges that tend to catch teams off guard in early development, and how those challenges can quietly grow into serious timeline, CMC, or IND-readiness problems when they're not caught early.

The conversation centers on three core development domains: analytical development, downstream purification, and drug product formulation. Speakers walk through where established platform approaches can do the heavy lifting, and where molecule-specific risks call for a more tailored strategy. The goal is practical and actionable — helping development teams understand how early decisions shape the balance among speed, quality, and risk, and ultimately determine how smoothly a program moves toward the clinic and beyond.